Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
IJU Case Rep ; 7(2): 157-160, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38440711

ABSTRACT

Introduction: Renal autotransplantation is considered a surgical procedure for extensive ureteral defects. Herein, we report a case of severe ureteral injury repaired by laparoscopic nephrectomy and renal autotransplantation with an iliac vein patch using bovine pericardium. Case presentation: A 56-year-old woman who had previously undergone gynecological surgery complained of right-sided abdominal pain. She was then later diagnosed with a right middle ureteral injury with a 5-cm long defect. We performed retroperitoneal laparoscopic nephrectomy and renal autotransplantation. As the iliac vein was fragile, venous patching using bovine pericardium was performed. The patient's renal function was well preserved after surgery. Conclusion: Laparoscopic nephrectomy and renal autotransplantation is an effective method for repairing severe ureteral injury with the preservation of renal function. A venous patch using bovine pericardium might be considered as a replacement for a fragile vein.

2.
IJU Case Rep ; 7(2): 131-135, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38440705

ABSTRACT

Introduction: Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment. Case presentation: The first case was of a 72-year-old woman who underwent robot-assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 90-week follow-up. The second case was of a 41-year-old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para-aortic lymph node. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 43-week follow-up. Conclusion: The outcomes of these cases indicate that avelumab-axitinib therapy has a long-term antitumor effect in some patients with tRCC.

3.
Jpn J Clin Oncol ; 54(4): 489-497, 2024 Apr 06.
Article in English | MEDLINE | ID: mdl-38157885

ABSTRACT

OBJECTIVE: The companion diagnosis for olaparib, a poly (ADP-ribose) polymerase inhibitor for prostate cancer, aims to detect BRCA1/2 gene variants. In clinical practice, the frequency of germline BRCA1/2 variants in patients receiving castration-resistant prostate cancer treatment is unknown. We aimed to evaluate the prevalence of germline BRCA1/2 variants and their relationship to prognosis and treatment efficacy in castration-resistant prostate cancer. METHODS: Between June 2021 and 2023, 92 patients receiving castration-resistant prostate cancer treatment were examined for germline BRCA1/2 variants using BRACAnalysis CDx®. Furthermore, the associations between BRCA1/2 pathogenic variants and clinical outcomes were assessed. RESULTS: Of the 92 patients referred for genetic testing, 6 (6.5%) carried germline pathogenic variants in BRCA1/2. The BRCA2 variant was the most frequent (n = 5), followed by BRCA1 variant (n = 1). Among the five variants in BRCA2, the p.Asp427Thrfs*3 variant was identified for the first time in prostate cancer. Overall survival from castration-resistant prostate cancer for patients with BRCA1/2 variants was significantly shorter than for patients without BRCA1/2 variants (P = 0.043). Progression-free survival of androgen receptor signaling inhibitors for patients with BRCA1/2 variants was significantly shorter than for those without (P = 0.003). Progression-free survival of taxane chemotherapy was significantly shorter in patients with BRCA1/2 variants than in those without (P = 0.0149). CONCLUSIONS: In clinical practice, 6.5% of patients treated with castration-resistant prostate cancer carried germline BRCA1/2 pathogenic variants. Japanese castration-resistant prostate cancer patients with germline BRCA1/2 mutants have a poor prognosis and may be less responsive to treatment with androgen receptor signaling inhibitors and taxane-based chemotherapy for castration-resistant prostate cancer.


Subject(s)
Antineoplastic Agents , Prostatic Neoplasms, Castration-Resistant , Male , Humans , BRCA1 Protein/genetics , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/genetics , Prostatic Neoplasms, Castration-Resistant/pathology , BRCA2 Protein/genetics , Receptors, Androgen/therapeutic use , Prevalence , Japan/epidemiology , Antineoplastic Agents/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use , Taxoids/therapeutic use , Germ Cells
4.
Ther Apher Dial ; 2023 Dec 12.
Article in English | MEDLINE | ID: mdl-38087844

ABSTRACT

INTRODUCTION: We aimed to determine whether unfractionated heparin (UH) and low molecular weight heparin (LH) contribute to aberrant carnitine metabolism in patients receiving hemodialysis. METHODS: The rate of increase in serum free fatty acids (FFAs) and the ratio of acylcarnitine to free carnitine (AC/FC) from before to after hemodialysis were determined in patients receiving UH and LH. Additionally, the effect of switching patients to UH from LH was examined. RESULTS: AC/FC was significantly higher in the UH group. In addition, serum FFAs in that group increased to 0.825 ± 0.270 after dialysis from 0.172 ± 0.160 before dialysis, showing a positive correlation with AC/FC. Furthermore, AC/FC was observed to be significantly higher in patients who were switched to UH from LH at 3 months after the change. CONCLUSION: Compared with UH, LH has a lesser effect on lipid metabolism, suggesting that it also has a lesser effect on carnitine metabolism.

6.
Hinyokika Kiyo ; 69(8): 227-232, 2023 Aug.
Article in Japanese | MEDLINE | ID: mdl-37667600

ABSTRACT

A 73-year-old man with renal cell carcinoma underwent a left-sided open radical nephrectomy at our center. The pathological diagnosis was Fuhrman Grade 2, stage pT3a, clear cell renal cell carcinoma. A follow-up computed tomography (CT) scan revealed lung metastases 9 months after the surgery. The patient was started on ipilimumab with nivolumab combination therapy; however, after two cycles of administration, he developed arthralgia and swelling of the knee. Furthermore, he developed diarrhea almost simultaneously, resulting in the interruption of the ipilimumab plus nivolumab treatment. We diagnosed arthritis and colitis with immune-related adverse events (irAE) and initiated steroid therapy with rehabilitation. His condition improved dramatically, and nivolumab treatment could be resumed after 3 months of treatment interruption.


Subject(s)
Arthritis , Carcinoma, Renal Cell , Colitis , Kidney Neoplasms , Male , Humans , Aged , Carcinoma, Renal Cell/drug therapy , Ipilimumab/adverse effects , Nivolumab/adverse effects , Kidney Neoplasms/drug therapy , Colitis/chemically induced
7.
Clin Exp Nephrol ; 27(12): 1010-1020, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37634218

ABSTRACT

BACKGROUND: Thrombotic microangiopathy (TMA) after kidney transplantation (KTx), particularly early onset de novo (dn) TMA, requires immediate interventions to prevent irreversible organ damage. This multicenter study was performed to investigate the allogeneic clinical factors and complement genetic background of dnTMA after KTx. METHODS: Perioperative dnTMA after KTx within 1 week after KTx were diagnosed based on pathological or/and hematological criteria at each center, and their immunological backgrounds were researched. Twelve aHUS-related gene variants were examined in dnTMA cases. RESULTS: Seventeen recipients (15 donors) were enrolled, and all dnTMA cases were onset within 72-h of KTx, and 16 of 17 cases were ABO incompatible. The implementation rate of pre-transplant plasmaphereses therapies were low, including cases with high titers of anti-A/anti-B antibodies. Examination of aHUS-related gene variants revealed some deletions and variants with minor allele frequency (MAF) in Japan or East Asian genome databases in genes encoding alternative pathways and complement regulatory factors. These variants was positive in 8 cases, 6 of which were positive in both recipient and donor, but only in one graft loss case. CONCLUSIONS: Although some immunological risks were found for dnTMA after KTx, only a few cases developed into TMA. The characteristic variations revealed in the present study may be novel candidates related to dnTMA in Japanese or Asian patients, but not pathogenic variants of aHUS. Future studies on genetic and antigenic factors are needed to identify factors contributing to dnTMA after KTx.


Subject(s)
Kidney Transplantation , Thrombotic Microangiopathies , Humans , Kidney Transplantation/adverse effects , Living Donors , East Asian People , Retrospective Studies , Thrombotic Microangiopathies/etiology , Thrombotic Microangiopathies/genetics , Complement System Proteins/genetics
8.
BJUI Compass ; 4(3): 339-345, 2023 May.
Article in English | MEDLINE | ID: mdl-37025472

ABSTRACT

Objectives: This study aims to investigate whether a cribriform pattern on prostate biopsy may be a factor in suspicion of intraductal carcinoma of the prostate after radical prostatectomy. Methods: This retrospective study assessed 100 men who underwent prostatectomy from 2015 to 2019. Participants were grouped as 76 patients with Gleason pattern 4 and 24 patients without this pattern. All 100 participants underwent retrograde radical prostatectomy and limited lymph node dissection. The same pathologist evaluated all specimens. The cribriform pattern was evaluated with haematoxylin and eosin counterstaining, and intraductal carcinoma of the prostate was evaluated with immunohistochemical analysis of cytokeratin 34ßE12. Results: Patients with intraductal carcinoma of the prostate on immunohistochemical analysis showed a significant tendency to relapse in the postoperative period, and those with the cribriform pattern on biopsy had a significant recurrence rate. In univariate and multivariate analyses, intraductal carcinoma of the prostate confirmed in biopsy tissue was an independent predictor of biochemical recurrence after prostatectomy. The rate of intraductal carcinoma of the prostate confirmation was 28% of cases with a cribriform pattern in biopsy tissue, which was increased to 62% in prostatectomy tissues. Conclusion: The cribriform pattern in the biopsy tissue may be a predictor for intraductal carcinoma of the prostate.

9.
Hinyokika Kiyo ; 68(2): 47-51, 2022 Feb.
Article in Japanese | MEDLINE | ID: mdl-35259863

ABSTRACT

A 75-year-old male visited a clinic with the chief complaint of pollakiuria. A computed tomography scan revealed, a left adrenal mass, and the patient was then referred to our hospital. Since a malignant tumor could not be ruled out. We performed laparoscopic left adrenal resection. Postoperative histopathological findings revealed the mass to be a bronchogenic cyst, which had no continuity with the normal adrenal gland. The postoperative course was uneventful, and recurrence has not been observed. Retroperitoneal bronchogenic cysts are rare and often difficult to diagnose preoperatively using imaging studies.


Subject(s)
Adrenal Gland Neoplasms , Bronchogenic Cyst , Adrenal Gland Neoplasms/pathology , Adrenal Glands , Aged , Bronchogenic Cyst/diagnostic imaging , Bronchogenic Cyst/surgery , Humans , Male , Retroperitoneal Space/diagnostic imaging , Retroperitoneal Space/pathology , Tomography, X-Ray Computed
10.
J Endourol ; 36(5): 641-646, 2022 05.
Article in English | MEDLINE | ID: mdl-34913764

ABSTRACT

Background: The long-term split renal function after robot-assisted partial nephrectomy (RAPN) is yet to be elucidated. This study aimed to assess long-term renal function of RAPN, using renal scintigraphy, and to identify clinical factors related to deterioration of renal function on the affected side of the kidney. Patients and Methods: RAPN for small tumors was performed, and split renal function was evaluated using 99m-Tc DTPA renal scintigraphy before and 1 year after surgery. Clinical factors (age, gender, body mass index, tumor side, presence of urinary protein, diabetes, hypertension, and dyslipidemia), perioperative factors (renal nephrectomy score [RNS], tumor diameter, overall surgery duration, console time, warm ischemic time, and amount of bleeding), and renal function (estimated glomerular filtration rate [eGFR] and glomerular filtration rate [GFR] measured using scintigraphy on both the affected and contralateral kidneys) were analyzed. Results: Sixty-six patients were included in the study. The median eGFR decreased from 71.9 to 63.9 mL/min after 1 year (p < 0.001), accounting for a mean loss of 10.1%. In scintigraphy examination, the median GFR on the affected kidney side decreased from 41.1 to 33.7 mL/min after 1 year (p < 0.001), accounting for a mean loss of 16.8%. RNS was significantly associated with renal function. Among RNS factors, the N factor is associated with renal function after RAPN. Conclusion: RNS, particularly the N factor, possibly influences the long-term deterioration of renal function after RAPN.


Subject(s)
Kidney Neoplasms , Robotic Surgical Procedures , Robotics , Glomerular Filtration Rate , Humans , Kidney/diagnostic imaging , Kidney/physiology , Kidney/surgery , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Nephrectomy , Radionuclide Imaging , Retrospective Studies , Technetium Tc 99m Pentetate , Treatment Outcome
11.
J Int Med Res ; 49(8): 3000605211037478, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34407681

ABSTRACT

OBJECTIVE: To investigate if the use of therapeutic agents for dysuria is a risk factor for the primary recurrence of non-muscle invasive bladder cancer (NMIBC). METHODS: First, patients with NMIBC were divided into two groups: the non-recurrence group and the recurrence group. Patient characteristics were compared between both groups. The risk factors of recurrence that were statistically different between the two groups were identified by multivariate analysis. Second, we divided the patients into risk and non-risk groups, and differences in the recurrence-free survival (RFS) between the two groups were analyzed before and after propensity score matching (PSM). RESULTS: A total of 162 patients were included, with 84 patients in the non-recurrence group and 78 patients in the recurrence group. In the multivariate analysis, the intake of dysuria agents and bacillus Calmette-Guérin (BCG) therapy were independent factors. The RFS results in terms of the intake of dysuria agents were statistically significant before and after PSM analysis, but no factors were significantly different between the BCG and non-BCG groups after PSM. CONCLUSIONS: Therapeutic agents for dysuria might be at an independent risk factor for NMIBC recurrence. This trial is registered with the UMIN Clinical Trials Registry under the number UMIN000036097 (https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno = R000041122).


Subject(s)
Urinary Bladder Neoplasms , Adjuvants, Immunologic , Dysuria/etiology , Humans , Neoplasm Invasiveness , Neoplasm Recurrence, Local/drug therapy , Prognosis , Propensity Score , Urinary Bladder Neoplasms/drug therapy
12.
IJU Case Rep ; 4(3): 127-131, 2021 May.
Article in English | MEDLINE | ID: mdl-33977237

ABSTRACT

INTRODUCTION: Clear cell papillary renal cell carcinoma often develops in the context of the dialyzed kidney (end-stage renal disease). However, the relationship between clear cell papillary renal cell carcinoma and microRNA expression in patients with end-stage renal disease remains unclear. CASE PRESENTATION: A left renal tumor measuring 22 mm was detected and a radical nephrectomy was performed on a 50-year-old man who had received hemodialysis for the past 6 years. A pathological diagnosis of pT1aNxMx, clear cell papillary renal cell carcinoma was made. We studied the expression of miR-155 in this case and compared it to the expression in nondialysis kidney tissue. The expression level of miR-155 was upregulated in tumor tissue compared with expression levels in the renal cortex for the present case. The expression level of miR-155 in the renal cortex was lower in the present case than in nondialysis kidney tissues. CONCLUSION: We demonstrated upregulation of miR-155 in a case of clear cell papillary renal cell carcinoma arising from end-stage renal disease.

13.
Ther Apher Dial ; 25(1): 44-49, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32281288

ABSTRACT

Indoxyl sulfate (IS) is related to the development of cardiovascular disease and total mortality in dialysis patients. High-performance liquid chromatography (HPLC) is the conventional measurement approach. However, the HPLC method is difficult to perform in real time. Recently, the IS Assay Kit "NIPRO", which enables the measuring of total IS by the enzyme method, was developed. This new reagent allows the easy and quick measurement of many samples using the automatic biochemical analyzer. Moreover, it was reported that it demonstrated satisfactory analytical performance. If this enzyme method is useful for measuring IS in hemodialysis, we can expect that the mechanism in which the IS effects adversely on a body as uremic toxins will be clarified. However, the enzyme method is more easily influenced by other coexisting substances. In this study, we have assessed on how the uremic toxins and anticoagulation effect on this new reagent and evaluate whether it can be put into practice effectively for hemodialysis patients. For the enzyme method, accuracy, simultaneous repeatability, linearity, limit of detection, influence of coexisting materials, and correlation with the HPLC method were examined. Accuracy and simultaneous repeatability were satisfactory, and linearity was good. The limit of detection was acceptable, and there was no influence of coexisting materials. With regard to the correlation, the regression equation was y = 0.947X + 7.987 and the correlation coefficient (r) was 0.972. This new reagent showed sufficient fundamental performance and had a good correlation with the conventional HPLC method for assessing the plasma of dialysis patients.


Subject(s)
Cardiovascular Diseases/blood , Clinical Enzyme Tests/methods , Indican/blood , Renal Dialysis , Biomarkers/blood , Chromatography, High Pressure Liquid , Disease Progression , Humans , Limit of Detection , Reproducibility of Results
14.
Low Urin Tract Symptoms ; 11(2): O98-O102, 2019 Apr.
Article in English | MEDLINE | ID: mdl-29845738

ABSTRACT

OBJECTIVE: The aim of the present study was to examine factors of nocturnal polyuria and blood pressure variability in male patients with lower urinary tract symptoms (LUTS) who were treated. METHODS: Two hundred and forty-two male patients with LUTS who were treated recorded frequency volume charts. We investigated their urinary condition and characteristics, medical history, and medications. Thirty-four of these patients underwent ambulatory blood pressure monitoring (ABPM) for 24 hours to evaluate blood pressure variability. RESULTS: In the present study, 194 patients (80.2%) had nocturia and 136 (56.2%) had nocturnal polyuria (NP). Among patients with nocturia (≥2 voids/night), 130 (67.0%) had nocturnal polyuria, and 26 of those with nocturia (13.4%) had reduced functional bladder capacity. The use of 2 or more antihypertensive medications was significantly higher in the NP than non-NP group (22.8% vs. 12.3%; P = .035). Significantly more patients in the NP group had non-dipping blood pressure (P = .037). Non-dipping blood pressure was considered a potential factor for NP. CONCLUSION: We suggest that treatment of non-dipping blood pressure may improve NP.


Subject(s)
Blood Pressure , Lower Urinary Tract Symptoms/physiopathology , Nocturia/etiology , Aged , Aged, 80 and over , Blood Pressure/physiology , Blood Pressure Monitoring, Ambulatory , Humans , Lower Urinary Tract Symptoms/therapy , Male , Nocturia/physiopathology , Urodynamics/physiology
15.
BMC Urol ; 18(1): 28, 2018 May 02.
Article in English | MEDLINE | ID: mdl-29716558

ABSTRACT

BACKGROUND: Reduced port laparoscopic surgery (RPLS) is comparable to conventional multiport laparoscopic surgery and has the potential to provide improved cosmesis and decreased pain; as such, it satisfies a growing demand for less invasive surgical procedures. Moreover, a zigzag incision of the umbilicus results in a less visible scar in plastic surgery. Here we report a series of two cases with bilateral organ tumors treated by single-stage RPLS using a combination of a transumbilical approach and a zigzag incision. CASE PRESENTATION: Case 1: A 63-year-old man was diagnosed with right renal cell carcinoma (RCC) (clear cell carcinoma, pT1a, venous invasion (-)) and a splenic tumor (cavernous hemangioma). Case 2: An 84-year-old woman was diagnosed with concurrent left RCC (clear cell carcinoma, pT1b, 65 × 65 mm, venous invasion (+)) and ascending colon cancer (adenocarcinoma pT3 with no nodal involvement (0/48)). The perioperative course was uneventful in both cases. However, an additional incision was required in Case 2 for specimen excision. Therefore, the scars were more obvious in Case 2 than in Case 1. CONCLUSIONS: Although more cases are required to evaluate the superiority of this technique, this novel procedure could be considered for patients with bilateral lesions.


Subject(s)
Carcinoma, Renal Cell/surgery , Kidney Neoplasms/surgery , Laparoscopy/methods , Splenic Neoplasms/surgery , Surgical Wound , Umbilicus/surgery , Aged, 80 and over , Carcinoma, Renal Cell/diagnostic imaging , Female , Humans , Kidney Neoplasms/diagnostic imaging , Male , Middle Aged , Splenic Neoplasms/diagnostic imaging
16.
Int J Urol ; 25(6): 630-632, 2018 06.
Article in English | MEDLINE | ID: mdl-29693280

ABSTRACT

Here, we report a case of a 68-year-old woman with cT4N0M1 (liver invasion and multiple lung metastases) metastatic renal cell carcinoma. We could carry out less invasive nephrectomy with partial hepatectomy because nivolumab administration as second-line therapy reduced the primary tumor remarkably. To the best of our knowledge, this is the first report of the use of nivolumab before carrying out surgery, and histological findings showed a pathological complete response.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Carcinoma, Renal Cell/drug therapy , Kidney Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Nivolumab/therapeutic use , Aged , Carcinoma, Renal Cell/secondary , Female , Humans , Kidney Neoplasms/pathology , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Neoadjuvant Therapy/methods , Nephrectomy/methods , Treatment Outcome
17.
Ther Apher Dial ; 22(5): 509-513, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29600601

ABSTRACT

Patients who undergo hemodialysis often suffer from cardiovascular disease (CVD), and evaluation of coronary artery calcification is extremely important. These evaluations are typically conducted using a noninvasive method including electron beam computed tomography (CT) or multi-detector CT, and the Agatston method to calculate the coronary artery calcification score (CACS). However, it is difficult to use for patients undergoing dialysis. Because patients undergoing dialysis is too strong in coronary artery calcification, and results become incorrect. Therefore, we were looking for a calcified evaluation place peculiar to a patients undergoing dialysis. We obtained pelvic artery calcification scores (PACS) using a 64-row multi-slice CT to assess the presence of calcification within a triangular space bordered by bordered by osseous structure. We used the Agatston method to calculate PACS. We compared male patients undergoing dialysis with male patients with normal renal function. Patients undergoing hemodialysis had a significantly higher incidence of pelvic artery calcification than normal controls (79.7% vs. 5.5%). In the dialysis group, CACS was 1660.2 (0-9056.1), and PACS was 48.8 (0-2943.1). We found a correlation between PACS and CACS and between PACS and dialysis period. We found penile artery calcification in male patients undergoing hemodialysis was more than normal controls, and it was possible to quantify PACS using the Agatston method. This study suggested the possibility that PACS became the vascular calcification evaluation method of the hemodialysis patient.


Subject(s)
Iliac Artery/pathology , Renal Dialysis/adverse effects , Tomography, X-Ray Computed/methods , Vascular Calcification/diagnostic imaging , Adult , Aged , Aged, 80 and over , Case-Control Studies , Humans , Iliac Artery/diagnostic imaging , Incidence , Male , Middle Aged , Multidetector Computed Tomography/methods , Pelvis/diagnostic imaging , Retrospective Studies , Vascular Calcification/epidemiology , Vascular Calcification/etiology
18.
Nihon Hinyokika Gakkai Zasshi ; 109(1): 35-39, 2018.
Article in Japanese | MEDLINE | ID: mdl-30662050

ABSTRACT

A 45-years-old man presented discharge of abscess from the umbilicus with lower abdominal pain. CT scan showed huge tumor from the bladder to the umbilical part with sigmoid colon invasion. He was diagnosed as urachal carcinoma, which was confirmed by pathological examination. We started FOLFOX chemotherapy according to advanced colon cancer. Approximately 80% of reduction was accomplished after 11 courses of FOLFOX. We performed radical cystectomy with sigmoid colon resection. Pathological examination revealed complete resection with negative surgical margin. No recurrence and metastasis were observed after 30 months of surgery. Urachal carcinoma is often advanced cancer when diagnosed. Effective chemotherapy is not established well. FOLFOX chemotherapy demonstrated the well antitumor effect in this case.


Subject(s)
Adenocarcinoma/pathology , Adenocarcinoma/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colon, Sigmoid/pathology , Colon, Sigmoid/surgery , Sigmoid Neoplasms/pathology , Sigmoid Neoplasms/therapy , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/therapy , Adenocarcinoma/diagnostic imaging , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Colectomy/methods , Colon, Sigmoid/diagnostic imaging , Combined Modality Therapy , Cystectomy/methods , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Male , Middle Aged , Neoplasm Invasiveness , Organoplatinum Compounds/administration & dosage , Sigmoid Neoplasms/diagnostic imaging , Tomography, X-Ray Computed , Treatment Outcome , Urinary Bladder Neoplasms/diagnostic imaging
19.
J Artif Organs ; 20(3): 230-235, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28357590

ABSTRACT

An electrical or water supply and a blood purification machine are required for renal replacement therapy. There is a possibility that acute kidney injury can occur in large numbers and on a wide scale in the case of a massive earthquake, and there is the potential risk that the current supply will be unable to cope with acute kidney injury cases. However, non-machinery dialysis requires exclusive circuits and has the characteristic of not requiring the full-scale dialysis machines. We performed perfusion experiments that used non-machinery dialysis and recent blood purification machines in 30-min intervals, and the effectiveness of non-machinery dialysis was evaluated by the assessing the removal efficiency of potassium, which causes lethal arrhythmia during acute kidney injury. The non-machinery dialysis potassium removal rate was at the same level as continuous blood purification machines with a dialysate flow rate of 5 L/h after 15 min and continuous blood purification machines with a dialysate flow rate of 3 L/h after 30 min. Non-machinery dialysis required an exclusive dialysate circuit, the frequent need to replace bags, and new dialysate exchanged once every 30 min. However, it can be seen as an effective renal replacement therapy for crush-related acute kidney injury patients, even in locations or facilities not having the full-scale dialysis machines.


Subject(s)
Acute Kidney Injury/therapy , Dialysis Solutions/pharmacology , Renal Dialysis/instrumentation , Equipment Design , Humans
20.
J Hum Genet ; 58(1): 21-6, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23151678

ABSTRACT

Tamsulosin hydrochloride is one of the most potent drugs for treatment of benign prostatic hyperplasia (BPH), however, the efficacy of tamsulosin hydrochloride varies among individuals. In this study, we measured the maximum serum concentration (Cmax) of tamsulosin hydrochloride in 182 of BPH patients and found remarkable individual variability. To investigate the genetic factors that regulate pharmacokinetics of tamsulosin hydrochloride, we conducted a genome-wide association study in these 182 BPH patients. As a result, rs16902947 on chromosome 5p13.2, rs7779057 on 7q22.3, rs35681285 on 7p21.2 and rs2122469 on 8p21.3 indicated possible associations with Cmax of tamsulosin hydrochloride (P=1.29 × 10(-7), 2.15 × 10(-7), 4.35 × 10(-7) and 7.03 × 10(-7), respectively), although these single-nucleotide polymorphisms (SNPs) did not reach the genome-wide significance threshold after Bonferroni correction. As these associated SNPs showed additive effects on serum tamsulosin hydrochloride concentration, we defined the 'Cmax prediction index' based on genotypes of these SNPs. This index clearly associated with Cmax values (P=4.5 × 10(-6)), indicating the possible roles of these four variants in tamsulosin hydrochloride pharmacokinetics. Our findings would partially explain the variability of the response to the tamsulosin hydrochloride treatment.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists/pharmacokinetics , Genetic Loci , Genome-Wide Association Study , Polymorphism, Single Nucleotide/genetics , Prostatic Hyperplasia/drug therapy , Prostatic Hyperplasia/genetics , Sulfonamides/pharmacokinetics , Adrenergic alpha-1 Receptor Antagonists/administration & dosage , Adrenergic alpha-1 Receptor Antagonists/therapeutic use , Aged , Aged, 80 and over , Asian People/genetics , Chromosomes, Human, Pair 5/genetics , Chromosomes, Human, Pair 7/genetics , Chromosomes, Human, Pair 8/genetics , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Sulfonamides/administration & dosage , Sulfonamides/therapeutic use , Tamsulosin
SELECTION OF CITATIONS
SEARCH DETAIL